Related Experiment Videos
Teniposide is not effective in chronic lymphocytic leukemia
Blut
|January 1, 1986
Summary
Teniposide showed no objective response in chronic lymphocytic leukemia (CLL) patients during a phase II trial. The drug was generally well-tolerated, with mild, primarily hematologic, toxicity observed.
Area of Science:
- Oncology
- Hematology
- Clinical Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Effective treatment options for CLL are crucial for patient outcomes.
- Teniposide is an established chemotherapeutic agent with known activity in other cancers.
Purpose of the Study:
- To evaluate the efficacy of Teniposide in patients with chronic lymphocytic leukemia.
- To assess the safety and tolerability of Teniposide in this patient population.
Main Methods:
- A phase II clinical trial was conducted.
- Sixteen consecutive patients with CLL were enrolled.
- Treatment involved Teniposide at a dosage of 100 mg/m2 administered weekly.
Main Results:
- No objective response was observed in any of the 16 treated patients.
- Toxicity was generally mild.
- The primary toxicity observed was hematologic.
Conclusions:
- Teniposide, at the tested dosage and schedule, demonstrated inactivity in chronic lymphocytic leukemia.
- Further investigation of Teniposide for CLL is not warranted at this dosage and schedule.